2021-02-06 02:00
Editor/Associated Finance Press
Original title: Global anti-epidemic re-spreading positive research shows that AstraZeneca vaccine is equally effective against new British variants. Source: Financial Associated Press
On November 23 last year, AstraZeneca announced the mid-term results of the vaccine’s Phase III trial. The average effective rate of the vaccine was 70%.
Andrew Pollard, the lead researcher of the Oxford vaccine trial, said on Friday that data from the latest ChAdOx1 vaccine trial conducted in the UK showed that the AstraZeneca/Oxford new crown vaccine can not only protect against the original virus, but also against the new variant B.1.1. 7.
The researchers tested blood samples from 256 subjects, and less than a third of the participants were infected with the new virus variant. Researchers finally found that in 75% of symptomatic infection cases, the vaccine can trigger an effective immune response against the new variant virus. If asymptomatic infection cases are included, about two-thirds of the cases can trigger an effective immune response. This preliminary research result has not yet been peer reviewed.
Sara Gilbert, head of the new crown vaccine research at the University of Oxford, said that although the vaccine is effective against the new variant virus discovered in the UK, it may need to adapt to future variants. We are working with AstraZeneca to optimize it if necessary.
Earlier this week, the University of Oxford also announced another positive. A study published on Wednesday showed that the AstraZeneca vaccine can significantly reduce the spread of the virus. According to the swabs collected by the researchers every week, the spread of the virus was reduced by 67% after the first dose of the vaccine. This is also important news for faster lifting of the epidemic blockade and promotion of economic recovery.
It is worth noting that the new British variant B.1.1.7 has an abnormally high number of mutations, which is not only more infectious, but also has evidence that the case fatality rate is 30%-40% higher. The chief scientific adviser of the United Kingdom, Patrick Vallance, said in late January: “For men in their sixties, an average of 10 out of 1,000 infected people will die unfortunately. But if the infection is a new variant The virus, about 13 or 14 deaths out of 1,000 infected people.”
–
Risk and disclaimer reminder: The above content only represents the author’s personal position and opinion, and does not represent any position of Huasheng, and Huasheng cannot confirm the authenticity, accuracy and originality of the above content. Before making any investment decision, investors should consider their own circumstances and consider the risks of investment products. If necessary, please consult professional investment advisors. Huasheng does not provide any investment advice, nor does it make any promises or guarantees.
.
